Status: Not yet recruiting
Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster with of 21-valent pneumococcal conjugate vaccine . Immune response will be assessed by opsonophagocytic assay reactivity.
Participants needed: 45
Trial details
Phase: Phase 4Biological sex: AllType: InterventionalSponsor: VA Sierra Nevada Health Care SystemUpdated: Aug 14, 2025
Eligibility criteria
Subject meets the CDC definition of an immunocompromising condition [+1]
Less than 5 years since last receipt of PPSV23 validated to patient medical reco... [+6]